top of page

Biopharma Daily Stock Updates - 07/05/22

$XBI $80.99 | +5.81%

Table of Contents:

Covid Updates


Pipeline Updates

#LXRX +41.8% (6/29) Lexicon Announces Positive Top-line Results from Phase 2 Proof-of-Concept Study of LX9211 in Painful Diabetic Neuropathy. source

#AVDL +40.1% (6/29) Avadel Pharmaceuticals Provides Corporate Update. source

#TALS +26.1% (6/30) Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update. source

#AGEN +23% (6/29) Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress. source

#EVFM +20.9% (6/30) Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO. source

#CGTX +18.2%

#ELDN +17.6%

#DYN +17.2% Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy. source

#NVAX +12.5% Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17. source

#FRLN +11.6%

#CDAK +11.6% CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine. source

#FULC +11.4% Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD). source

#ARWR +8.9% Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE. source

#AMAM +7.9%

#AMTI +7.6% Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

#KDNY +4.6% Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN). source

#ADXN +0.8%

#AYLA -0.2% Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors. source

#KALV -0.5% KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program. source

#ANEB -3.6% Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication. source

#ENDP -8.8% Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor. source

#OMER -33.4%


Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*


Business Updates

#ENOB +17.6% Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data. source

#PGEN +14.9% Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics. source

#ISEE +8.0% Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®. source

#SYRS -4.4% & #TYME +8.1% Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement. source


Posted by FS/JM



bottom of page